糖尿病候选药物FGF-21的研究进展

Research progress of the diabetes drug FGF-21

世界卫生组织的调查报告显示糖尿病是导致人类死亡的三大主要原因之一。糖尿病患者基数大、传统药物治疗专一性不足,因此高效、专一、副作用小的糖尿病药物成为药物研究的热点问题。人成纤维细胞生长因子-21(FGF-21)是由FGF基因家族成员编码的细胞生长因子,具有广泛的生物学活性。研究表明其可以独立于胰岛素摄取葡萄糖,并与胰岛素有协同作用;可以显著降低血糖及血脂水平,改善胰岛素抵抗和胰岛β细胞功能。随着研究的深入,FGF-21将有望成为与胰岛素替代、竞争或联合用药的2型糖尿病治疗的一线药物。本文对FGF-21的结构、功能和现阶段研究进展分别进行了阐述。

The World Health Organization’s survey shows that diabetes is one of the three major causes of human deaths.Because of the large number of patients with diabetes,the traditional medicine treatment is less specific,the dia-betes drugs with high efficiency,specificity and side effects is the hot issues of drug research.Fibroblast growth factor-21（FGF-21） is a cell growth factor encoded by the members of the FGF gene family, and has a wide range of biological activity.The study shows that it can be independent of the insulin,and have a synergistic effect with insulin.It can sig-nificantly reduce blood glucose and blood lipid levels,improve insulin resistance and islet β-cell function.With the in-depth study,FGF-21 is expected to become a first-line drug with insulin replacement,competition or combination of type 2 diabetes treatment.This paper describes the structure,function and current research progress of FGF-21.